Akshai Lakhanpal
Internal Medicine · Plano, TXNPI 1700147683
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 99 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by Novo Nordisk at 28.6% of the total. Reporting peaked in 2021 at $628 and has fallen 67.1% since, to $207 in 2025.
Across 99 payments — averaging $17.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$491
- Amarin Pharma, Inc.$289
- Boehringer Ingelheim$166
- AstraZeneca$130
- GSK$121
- Merck$111
- plus $411 from 16 others
Across 25 payments — averaging $85.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim International GmbH$2K
What the payments were for
- Food & beverage$1,717100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 28 | $491 |
| Amarin Pharma, Inc. | 15 | $289 |
| Boehringer Ingelheim | 9 | $166 |
| AstraZeneca | 9 | $130 |
| GSK | 8 | $121 |
| Merck | 7 | $111 |
| Bayer | 4 | $74 |
| Abbott | 3 | $46 |
| Amgen | 2 | $35 |
| Phadia US Inc. | 2 | $26 |
| Dexcom, Inc. | 1 | $25 |
| Nabriva Therapeutics, PLC | 1 | $22 |
| Genentech USA, Inc. | 1 | $21 |
| Pfizer | 1 | $21 |
| Novartis | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Mylan Specialty L.p. | 1 | $19 |
| Medtronic | 1 | $19 |
| Antares Pharma, Inc. | 1 | $19 |
| Johnson & Johnson | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Lilly USA, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$110
How this compares
$1,717 in reported general payments places this provider in the 75th percentile of 7,675 internal medicine providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 90 | $125,414 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 11 | $49,449 |
| OzempicSemaglutide | 25 | $45,644 |
| MyrbetriqMirabegron | 16 | $20,542 |
| SymbicortBudesonide/Formoterol Fumarate | 23 | $11,615 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 107 | $3,546 |
| BreynaBudesonide/Formoterol Fumarate | 14 | $2,899 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $1,730 |
| Atorvastatin Calcium | 216 | $1,519 |
| Lidocaine | 14 | $1,203 |
| Rosuvastatin Calcium | 107 | $1,178 |
| Gabapentin | 56 | $1,149 |
| Fluticasone Propionate | 44 | $1,112 |
| Lisinopril | 168 | $922 |
| Tamsulosin Hcl | 33 | $800 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $166 | $125,41490 claims |
| Novo NordiskOzempic | $491 | $45,64425 claims |
| AstraZenecaSymbicort | $130 | $11,61523 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Plano
- Ayesha AmanPlano$133K
- Spencer BerthelsenSugar Land$891K
- Hameed AliTemple$773K
- Marc TribbleDallas$693K
- Gary SinclairDallas$599K
- Mohammed Al-NajjarEl Paso$586K
- Han SchmidlyDallas$465K
- Hussein TawbiHouston$365K
- Hans LeeHouston$327K
- Tapan KadiaHouston$311K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.